Manuela Rabaglio

7.5k total citations
83 papers, 2.0k citations indexed

About

Manuela Rabaglio is a scholar working on Genetics, Oncology and Cancer Research. According to data from OpenAlex, Manuela Rabaglio has authored 83 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Genetics, 36 papers in Oncology and 36 papers in Cancer Research. Recurrent topics in Manuela Rabaglio's work include Estrogen and related hormone effects (28 papers), Breast Cancer Treatment Studies (24 papers) and BRCA gene mutations in cancer (14 papers). Manuela Rabaglio is often cited by papers focused on Estrogen and related hormone effects (28 papers), Breast Cancer Treatment Studies (24 papers) and BRCA gene mutations in cancer (14 papers). Manuela Rabaglio collaborates with scholars based in Switzerland, United States and Italy. Manuela Rabaglio's co-authors include Alan S. Coates, Aron Goldhirsch, Richard D. Gelber, Karen N. Price, Beat Thürlimann, Marco Colleoni, John Forbes, Ian Smith, Meredith M. Regan and Bent Ejlertsen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Manuela Rabaglio

76 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manuela Rabaglio Switzerland	22	1.2k	819	779	589	298	83	2.0k
Yasuo Hozumi Japan	23	964 0.8×	704 0.9×	549 0.7×	522 0.9×	328 1.1×	84	1.9k
Monica Castiglione Switzerland	17	1.4k 1.2×	1.3k 1.6×	1.3k 1.6×	522 0.9×	258 0.9×	26	2.4k
Lucy Kilburn United Kingdom	15	1.1k 0.9×	863 1.1×	613 0.8×	1.1k 1.9×	347 1.2×	64	2.1k
Erhard Quebe‐Fehling Switzerland	15	1.2k 1.0×	614 0.7×	639 0.8×	393 0.7×	228 0.8×	42	1.9k
G Hoctin-Boes Netherlands	8	1.4k 1.1×	958 1.2×	1.5k 1.9×	392 0.7×	278 0.9×	12	2.4k
Reena S. Cecchini United States	20	1.8k 1.5×	959 1.2×	1.1k 1.3×	422 0.7×	393 1.3×	49	2.9k
A. Buzdar United States	7	1.2k 1.0×	846 1.0×	1.2k 1.6×	356 0.6×	253 0.8×	16	2.0k
Ellen Schlichting Norway	21	834 0.7×	676 0.8×	457 0.6×	213 0.4×	420 1.4×	44	1.6k
Ted Vandenberg Canada	19	1.4k 1.2×	761 0.9×	279 0.4×	585 1.0×	381 1.3×	39	2.0k
D. Amoroso Italy	23	2.0k 1.7×	925 1.1×	668 0.9×	791 1.3×	455 1.5×	104	2.8k

Countries citing papers authored by Manuela Rabaglio

Since Specialization

Citations

This map shows the geographic impact of Manuela Rabaglio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuela Rabaglio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuela Rabaglio more than expected).

Fields of papers citing papers by Manuela Rabaglio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuela Rabaglio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuela Rabaglio. The network helps show where Manuela Rabaglio may publish in the future.

Co-authorship network of co-authors of Manuela Rabaglio

This figure shows the co-authorship network connecting the top 25 collaborators of Manuela Rabaglio. A scholar is included among the top collaborators of Manuela Rabaglio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuela Rabaglio. Manuela Rabaglio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klose, Martina, Simon Haefliger, Manuela Rabaglio, et al.. (2025). 35P TLD-1 – A novel liposomal doxorubicin formulation, in patients with advanced solid tumors: Final results of a multicenter, open-label, cross-over phase I study (SAKK 65/16). ESMO Open. 10. 104193–104193. 1 indexed citations

Solaß, Wiebke, Manuela Rabaglio, Tilman T. Rau, et al.. (2024). Real-World Data on Institutional Implementation of Screening for Mismatch Repair Deficiency and Lynch Syndrome in Endometrial Cancer Patients. Cancers. 16(3). 671–671.

Colombo, Ilaria, Simon Haefliger, Manuela Rabaglio, et al.. (2024). TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). European Journal of Cancer. 201. 113588–113588. 10 indexed citations

Röthlisberger, Benno, et al.. (2023). A New de novo BRCA1 Mutation in a Young Breast Cancer Patient: A Case Report. The Application of Clinical Genetics. Volume 16. 83–87. 3 indexed citations

Goodwin, Pamela J., Bingshu E. Chen, Karen A. Gelmon, et al.. (2023). Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. Journal of Clinical Oncology. 41(35). 5356–5362. 11 indexed citations

Rausch, Christian, Ulrike Bacher, Manuela Rabaglio, et al.. (2022). Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study. Journal of Clinical Medicine. 11(18). 5378–5378. 2 indexed citations

Goodwin, Pamela J., Ryan J.O. Dowling, Marguerite Ennis, et al.. (2021). Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectrum. 5(5). 12 indexed citations

Leone, José Pablo, Bernard F. Cole, Meredith M. Regan, et al.. (2020). Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial. Cancer. 127(5). 700–708. 5 indexed citations

Hess, Dagmar, Ilaria Colombo, Simon Haefliger, et al.. (2020). 575P TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumours: Dose escalation part of a multicenter open-label phase I trial (SAKK 65/16). Annals of Oncology. 31. S490–S490. 2 indexed citations

10.

Colombo, Nicoletta, Yoland Antill, M.P. Barretina Ginesta, et al.. (2020). 884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. Annals of Oncology. 31. S647–S647. 3 indexed citations

11.

Zimmermann, Bettina, et al.. (2020). Examining information-seeking behavior in genetic testing for cancer predisposition: A qualitative interview study. Patient Education and Counseling. 104(2). 257–264. 8 indexed citations

12.

Rabaglio, Manuela, Zhuoxin Sun, Rudolf Maibach, et al.. (2020). Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast Cancer Research and Treatment. 185(3). 697–707. 8 indexed citations

13.

Dziadziuszko, Rafał, Egbert F. Smit, Urania Dafni, et al.. (2019). Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Journal of Thoracic Oncology. 14(6). 1086–1094. 107 indexed citations

14.

Loi, Shrushma, Anita Giobbie‐Hurder, Andrea Gombos, et al.. (2017). Phase Ib/II study evaluating safety and efficacy of Pembrolizumab and Trastuzumab in patients with Trastuzumab-resistant HER2-positive advanced breast cancer : results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014). Open Repository and Bibliography (University of Liège). 5 indexed citations

15.

Huober, Jens, Bernard F. Cole, Manuela Rabaglio, et al.. (2013). Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Research and Treatment. 143(1). 159–169. 33 indexed citations

16.

Ewertz, Marianne, Kathryn P. Gray, Meredith M. Regan, et al.. (2012). Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial. Journal of Clinical Oncology. 30(32). 3967–3975. 102 indexed citations

17.

Aebi, Stefan, Zijie Sun, Danielle Braun, et al.. (2011). Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. Annals of Oncology. 22(9). 1981–1987. 46 indexed citations

18.

Rabaglio, Manuela, Zijie Sun, Karen N. Price, et al.. (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of Oncology. 20(9). 1489–1498. 133 indexed citations

19.

Mouridsen, Henning T., Aparna Keshaviah, Alan S. Coates, et al.. (2007). Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial. Journal of Clinical Oncology. 25(36). 5715–5722. 93 indexed citations

20.

Mauriac, L., Aparna Keshaviah, Marc Debled, et al.. (2007). Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Annals of Oncology. 18(5). 859–867. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact